Literature DB >> 16360483

Combined analysis of morphology and fluorescence in situ hybridization significantly increases accuracy of bladder cancer detection in voided urine samples.

Michal Daniely1, Ronny Rona, Tal Kaplan, Shirley Olsfanger, Lea Elboim, Yulia Zilberstien, Avner Friberger, Dvora Kidron, Eran Kaplan, Sylvia Lew, Ilan Leibovitch.   

Abstract

OBJECTIVES: To evaluate a combined analysis approach that involves cytologic evaluation and fluorescence in situ hybridization analysis for detecting cancer cells in voided urine samples using an automated scanning station.
METHODS: Voided urine samples from 41 patients suspected of having transitional cell carcinoma were stained with May-Grünwald Giemsa stain, scanned for atypical or suspicious cells, destained, and hybridized with a mixture of fluorescent-labeled probes. Samples were tested using either the UroVysion probe or by a mix of chromosomes 3, 7, and 17 centromeric probes. A case was regarded as positive when at least one cell was abnormal in both aspects, morphology and fluorescence in situ hybridization. Patients were evaluated concomitantly by cytology, cytoscopy, and biopsy, if indicated.
RESULTS: Overall, 26 samples were positive by combined analysis. Biopsy-proven transitional cell carcinoma was positive by combined analysis in all cases (100%) and in 13 cases (61.9%) by cytology (P = 0.0133). The advantage of the combined analysis was noted mostly in low-grade and superficial tumors for which the sensitivity of cytology reached 30% (P = 0.023) and 27.27% (P = 0.0133), respectively. Specificity was 100%.
CONCLUSIONS: Our results have shown that combined analysis for the presence of transitional cell carcinoma cells is a powerful tool, providing high sensitivity and specificity, and may offer a new scheme for bladder cancer management.

Entities:  

Mesh:

Year:  2005        PMID: 16360483     DOI: 10.1016/j.urology.2005.07.016

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Genetically abnormal circulating cells in lung cancer patients: an antigen-independent fluorescence in situ hybridization-based case-control study.

Authors:  Ruth L Katz; Weigong He; Abha Khanna; Ricardo L Fernandez; Tanweer M Zaidi; Matthew Krebs; Nancy P Caraway; Hua-Zhong Zhang; Feng Jiang; Margaret R Spitz; David P Blowers; Carlos A Jimenez; Reza J Mehran; Stephen G Swisher; Jack A Roth; Jeffrey S Morris; Carol J Etzel; Randa El-Zein
Journal:  Clin Cancer Res       Date:  2010-07-22       Impact factor: 12.531

2.  Integrating a FISH imaging system into the cytology laboratory.

Authors:  G Denice Smith; Matt Riding; Kim Oswald; Joel S Bentz
Journal:  Cytojournal       Date:  2010-04-06       Impact factor: 2.091

3.  Biomarkers for detection and surveillance of bladder cancer.

Authors:  Lorne I Budman; Wassim Kassouf; Jordan R Steinberg
Journal:  Can Urol Assoc J       Date:  2008-06       Impact factor: 1.862

Review 4.  Comparison of the clinical usefulness of different urinary tests for the initial detection of bladder cancer: a systematic review.

Authors:  Alessandro Sciarra; Giovanni Di Lascio; Francesco Del Giudice; Pier Paolo Leoncini; Stefano Salciccia; Alessandro Gentilucci; Angelo Porreca; Benjamin I Chung; Giovanni Di Pierro; Gian Maria Busetto; Ettore De Berardinis; Martina Maggi
Journal:  Curr Urol       Date:  2021-03-29

5.  A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection.

Authors:  Hugh J Lavery; Boriana Zaharieva; Andrew McFaddin; Nyla Heerema; Kamal S Pohar
Journal:  BMC Cancer       Date:  2017-04-07       Impact factor: 4.430

Review 6.  Review of the Clinical Approaches to the Use of Urine-based Tumor Markers in Bladder Cancer.

Authors:  Timothy Clinton; Yair Lotan
Journal:  Rambam Maimonides Med J       Date:  2017-10-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.